RBC Capital raised the firm’s price target on Johnson & Johnson to $240 from $230 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that JNJ appears poised to be a top-tier grower in MedTech with its strategy around “portfolio shifting” and “focused innovation” to participate in higher-growth end-markets.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Rival Medline Pulls Off $6B IPO, Topping 2025 Deal Table
- 3 Best ETFs to Invest In, According to AI Analyst, 12/15/2025
- Johnson & Johnson price target raised to $220 from $204 at BofA
- Balanced Risk-Reward Profile for Johnson & Johnson Amid Limited Stock Re-Rating Potential
- Johnson & Johnson announces FDA approved sNDA for AKEEGA plus prednisone